---
document_datetime: 2025-11-23 08:37:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/solumarv-0.html
document_name: solumarv-0.html
version: success
processing_time: 0.0660999
conversion_datetime: 2025-12-26 19:36:43.723413
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Solumarv

[RSS](/en/individual-human-medicine.xml/66429)

##### Refused

This medicine has been refused authorisation

insulin human

Medicine

Human

Refused

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Solumarv](#news-on)
- [Related content](#related-content-699)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 19 November 2015, the Committee for Medicinal Products for Human Use (CHMP) recommended the refusal of the marketing authorisation for the medicinal product Solumarv, intended for the treatment of diabetes.

The company that applied for authorisation is Marvel Lifesciences Ltd. It can request a re-examination of the opinion within 15 days of receipt of notification of this negative opinion.

Expand section

Collapse section

## What was Solumarv expected to be used for?

Solumarv was expected to be used to treat patients with diabetes who require insulin to control their blood sugar levels.

## How is Solumarv expected to work?

Diabetes is a condition in which the body does not produce enough insulin to control the level of blood sugar or in which the body is unable to use insulin effectively. Solumarv was intended as a replacement for the insulin made by the body.

## What did the company present to support its application?

The company presented results of studies in healthy people designed to show that Solumarv is similar to its reference medicine Humulin S in terms of biological activity and how the body handles the medicine. Two additional studies in patients with type 1 and type 2 diabetes compared the safety and effectiveness of Solumarv and Humulin S.

## What were the CHMP's main concerns that led to the refusal?

The CHMP's main concern was that the company did not define the manufacturing process for Solumarv in sufficient detail. As such, it was not possible to show that Solumarv used in clinical studies was representative of batches intended for the market and that its quality was comparable to Humulin S's.

The CHMP concluded that Solumarv could not be approved as a biosimilar of Humulin S and recommended that it be refused marketing authorisation.

## What consequences does this refusal have for patients in clinical trials or compassionate use programmes?

The company informed the CHMP that there are no clinical trials or compassionate use programmes affected by the Committee's opinion.

Questions and answers on refusal of the marketing authorisation for Solumarv (insulin human)

Adopted

Reference Number: EMA/765377/2015

English (EN) (71.87 KB - PDF)

**First published:** 20/11/2015

**Last updated:** 20/11/2015

[View](/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_en.pdf)

[Other languages (22)](#file-language-dropdown-907)

български (BG) (119.03 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_bg.pdf)

español (ES) (111.57 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_es.pdf)

čeština (CS) (113.31 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_cs.pdf)

dansk (DA) (112.14 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_da.pdf)

Deutsch (DE) (114.32 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_de.pdf)

eesti keel (ET) (110.18 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_et.pdf)

ελληνικά (EL) (120.77 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_el.pdf)

français (FR) (112.63 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_fr.pdf)

hrvatski (HR) (112.21 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_hr.pdf)

italiano (IT) (110.94 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_it.pdf)

latviešu valoda (LV) (124.86 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_lv.pdf)

lietuvių kalba (LT) (113.11 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_lt.pdf)

magyar (HU) (112.56 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_hu.pdf)

Malti (MT) (115.38 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_mt.pdf)

Nederlands (NL) (112.04 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_nl.pdf)

polski (PL) (113.8 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_pl.pdf)

português (PT) (112.58 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_pt.pdf)

română (RO) (111.95 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_ro.pdf)

slovenčina (SK) (113.23 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_sk.pdf)

slovenščina (SL) (112.21 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_sl.pdf)

Suomi (FI) (110.31 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_fi.pdf)

svenska (SV) (111.2 KB - PDF)

**First published:**

20/11/2015

**Last updated:**

20/11/2015

[View](/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_sv.pdf)

## Product details

Name of medicine Solumarv Active substance Insulin human International non-proprietary name (INN) or common name insulin human Therapeutic area (MeSH) Diabetes Mellitus Anatomical therapeutic chemical (ATC) code A10AB01

## Application details

EMA product number EMEA/H/C/003858

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation applicant Marvel Lifesciences Ltd Opinion adopted 19/11/2015 Refusal of marketing authorisation 11/02/2016

## Assessment history

Solumarv : EPAR - Public assessment report

Adopted

Reference Number: EMA/596513/2015

English (EN) (1.55 MB - PDF)

**First published:** 16/02/2016

**Last updated:** 16/02/2016

[View](/en/documents/assessment-report/solumarv-epar-public-assessment-report_en.pdf)

#### News on Solumarv

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 November 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-november-2015) 20/11/2015

#### Related content

- [Biosimilar medicines](/en/human-regulatory/overview/biosimilar-medicines)

#### Topics

- [Biosimilars](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A45)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 16/02/2016

## Share this page

[Back to top](#main-content)